Welcome to our dedicated page for Forte Biosciences SEC filings (Ticker: FBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Forte Biosciences, Inc. filings document a clinical-stage biopharmaceutical issuer focused on FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases. Its 8-K reports cover operating and financial results, Regulation FD clinical disclosures, material events, capital-structure matters and exhibits such as press releases and clinical presentations.
Proxy materials describe annual meeting matters, stockholder voting, board and compensation governance and equity incentive plan administration. The filing record also identifies Forte’s common stock, par value $0.001 per share, listed on Nasdaq under the symbol FBRX.
Forte Biosciences (Common Stock) Schedule 13G: Adage Capital Management and affiliated reporting persons disclose beneficial ownership of 950,000 shares of common stock, representing 6.84% of the class based on 13,885,668 shares outstanding as of March 27, 2026. The shares are directly held by Adage Capital Partners, L.P. and reported with shared voting and shared dispositive power by the named reporting persons.
The filing identifies the reporting persons, their business address, and the CUSIP 34962G208. Ownership percentages and the outstanding share base are taken from the company’s Annual Report on Form 10-K for the year ended December 31, 2025, as referenced in the statement.
Forte Biosciences, Inc. reported a net loss of $22.1 million for the three months ended March 31, 2026, wider than the prior-year period, as it ramped spending on its lead autoimmune antibody FB102.
Research and development expenses rose to $20.5 million, driven by a Phase 2 trial in celiac disease and Phase 1b trials in non-segmental vitiligo and alopecia areata, while general and administrative expenses declined to $2.0 million, helped by a $2.3 million interim insurance recovery related to litigation defense costs. Cash and cash equivalents were $58.2 million as of March 31, 2026, with operating cash outflows of $18.8 million in the quarter.
After quarter-end, Forte strengthened its balance sheet through an April 2026 equity offering generating $172.5 million in gross proceeds and $162.1 million in net proceeds before other offering expenses, and believes this funding, together with existing cash, will support operations for at least twelve months from the filing date while advancing FB102 through ongoing clinical trials.
Forte Biosciences, Inc. reported a net loss of $22.1 million for the three months ended March 31, 2026, wider than the prior-year period, as it ramped spending on its lead autoimmune antibody FB102.
Research and development expenses rose to $20.5 million, driven by a Phase 2 trial in celiac disease and Phase 1b trials in non-segmental vitiligo and alopecia areata, while general and administrative expenses declined to $2.0 million, helped by a $2.3 million interim insurance recovery related to litigation defense costs. Cash and cash equivalents were $58.2 million as of March 31, 2026, with operating cash outflows of $18.8 million in the quarter.
After quarter-end, Forte strengthened its balance sheet through an April 2026 equity offering generating $172.5 million in gross proceeds and $162.1 million in net proceeds before other offering expenses, and believes this funding, together with existing cash, will support operations for at least twelve months from the filing date while advancing FB102 through ongoing clinical trials.
Forte Biosciences, Inc. is soliciting proxies for its 2026 virtual annual meeting on May 29, 2026, where holders of 20,478,817 shares of common stock as of April 17, 2026 may vote.
Stockholders will elect three Class III directors (Steven Kornfeld, Scott Brun, and CEO Paul Wagner), ratify KPMG LLP as auditor, cast an advisory say-on-pay vote, and consider approval of an amended and restated 2021 equity incentive plan. The plan would add 1,850,000 shares for equity awards, about 7.5% of 24,435,659 fully diluted shares, to support employee and director incentives. The proxy also describes board independence, committee structure, director pay, and Dr. Barbara Finck’s separate consulting arrangement.
Forte Biosciences files a prospectus supplement registering 5,709,936 shares of common stock. The offering is priced at $26.27 per share for aggregate gross proceeds of approximately $150.0M; net proceeds to the company before expenses are about $141.0M. The underwriters have a 30‑day option to purchase up to an additional 856,490 shares.
The company states it will use net proceeds primarily for working capital and clinical development of its lead candidate FB102, and had cash and cash equivalents of approximately $77.0M as of December 31, 2025. The prospectus supplement summarizes recent Phase 1/1b clinical results in celiac disease and ongoing development plans for vitiligo, alopecia areata and type 1 diabetes.
Forte Biosciences, Inc. entered an underwriting agreement for a public offering of 5,709,936 shares of common stock at $26.27 per share, targeting gross proceeds of about $150 million. Underwriters have a 30-day option to buy up to 856,490 additional shares.
The company expects net proceeds of roughly $141 million, or $162 million if the option is fully exercised, after underwriting discounts and commissions. All shares are being sold by Forte, and the deal is expected to close on or about April 10, 2026, subject to customary conditions.
The offering is made under an effective Form S-3 shelf registration. Forte plans to use the cash mainly for working capital and general corporate purposes, including clinical development of its FB102 autoimmune program and related research activities.
Forte Biosciences is offering shares of its common stock pursuant to a shelf prospectus supplement dated April 8, 2026. The supplement describes an at‑the‑market style primary offering of common stock on Nasdaq (symbol FBRX), with underwriting arrangements and a 30‑day overallotment option; specific share counts and per‑share public offering price are left blank in the provided excerpt. The prospectus supplement highlights clinical progress for lead candidate FB102, including completed Phase 1 healthy volunteer cohorts, positive Phase 1b celiac disease results (32 subjects, randomized 3:1), initiation of a Phase 2 celiac trial with topline readout expected in 2026, and ongoing Phase 1b studies in vitiligo and alopecia areata. The company had approximately 12,948,308 shares outstanding as of December 31, 2025 and reported approximately $77.0 million in cash and cash equivalents as of that date.
Forte Biosciences is offering shares of its common stock pursuant to a shelf prospectus supplement dated April 8, 2026. The supplement describes an at‑the‑market style primary offering of common stock on Nasdaq (symbol FBRX), with underwriting arrangements and a 30‑day overallotment option; specific share counts and per‑share public offering price are left blank in the provided excerpt. The prospectus supplement highlights clinical progress for lead candidate FB102, including completed Phase 1 healthy volunteer cohorts, positive Phase 1b celiac disease results (32 subjects, randomized 3:1), initiation of a Phase 2 celiac trial with topline readout expected in 2026, and ongoing Phase 1b studies in vitiligo and alopecia areata. The company had approximately 12,948,308 shares outstanding as of December 31, 2025 and reported approximately $77.0 million in cash and cash equivalents as of that date.
Forte Biosciences, Inc. chief financial officer Antony A. Riley exercised restricted stock units that converted into 375 shares of Common Stock on April 1, 2026. These RSUs had a conversion price of $0.00 per share, reflecting equity compensation rather than an open-market purchase.
To cover tax obligations from the vesting, 134 Common Shares were withheld at $24.86 per share, which is treated as a tax-withholding disposition rather than a traditional stock sale. After these transactions, Riley directly held 41,982 Common Shares and 1,125 RSUs, representing ongoing equity exposure to the company.
Forte Biosciences, Inc. director and officer Paul A. Wagner reported routine equity compensation activity. On April 1, 2026, 1,250 restricted stock units vested and were exercised into an equal number of common shares at a stated price of $0.00 per share.
To cover tax obligations on this vesting, 98 common shares were withheld at $24.86 per share, a non-market tax-withholding disposition rather than an open-market sale. After these transactions, Wagner directly holds 84,330 common shares and 3,750 RSUs, reflecting a net increase in his equity position.
The RSUs vest in installments, with one-sixteenth of the award vesting on each Quarterly Vesting Date—January 1, April 1, July 1, and October 1—under the company’s 2021 Equity Incentive Plan, so similar compensation-related transactions may continue as future tranches vest.
Forte Biosciences reported a larger 2025 net loss as it ramped investment in lead drug FB102. Net loss was $69.4 million versus $35.5 million in 2024, or $(4.71) per share versus $(12.17).
Research and development expenses rose to $58.2 million from $21.2 million, mainly from FB102 phase 2 celiac and phase 1b vitiligo and alopecia trials. General and administrative expenses declined to $12.4 million from $15.4 million, helped by lower professional and legal costs.
Forte ended 2025 with $77.0 million in cash and cash equivalents. As of December 31, 2025, there were 12.9 million common shares and 4.9 million prefunded warrants outstanding. The company highlighted multiple FB102 clinical readouts expected in 2026 across celiac disease, vitiligo and alopecia areata.